Elite in Scleroderma

Dr. Robyn T. Domsic

Rheumatology
University Of Pittsburgh Physicians
3471 5th Ave, 
Pittsburgh, PA 
 (237.8 mi)
Offers Telehealth
Elite in Scleroderma
University Of Pittsburgh Physicians
3471 5th Ave, 
Pittsburgh, PA 
 (237.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

Robyn Domsic is a Rheumatologist in Pittsburgh, Pennsylvania. Dr. Domsic and is rated as an Elite provider by MediFind in the treatment of Scleroderma. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Raynaud Phenomenon, and Scleroma.

Her clinical research consists of co-authoring 95 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 86 articles and participated in 7 clinical trials in the study of Scleroderma.

Specialties
Rheumatology
Licenses
Internal Medicine in PA
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Upmc St Margaret
Upmc Passavant
The Washington Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
3471 5th Ave, Pittsburgh, PA 15213
Other Locations
UNIVERSITY OF PITTSBURGH PHYSICIANS
200 Lothrop St, Pittsburgh, PA 15213
UNIVERSITY OF PITTSBURGH PHYSICIANS
200 Delafield Rd, Pittsburgh, PA 15215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: February 05, 2024
Intervention Type: Drug
Study Phase: Phase 2
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Enrollment Status: Completed
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drugs: Pirfenidone, Mycophenolate Mofetil
Study Phase: Phase 2
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 18, 2022
Intervention Type: Drug
Study Drug: JBT-101
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis
Enrollment Status: Completed
Publish Date: August 12, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multi-center Randomized, Double Blind, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Riociguat in Scleroderma - Associated Digital Ulcers
A Multi-center Randomized, Double Blind, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Riociguat in Scleroderma - Associated Digital Ulcers
Enrollment Status: Completed
Publish Date: September 24, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

95 Total Publications

IP-to-MS: An Unbiased Workflow for Antigen Profiling.
IP-to-MS: An Unbiased Workflow for Antigen Profiling.
Journal: Journal of proteome research
Published: January 15, 2025
Similar Doctors
Elite in Scleroderma
Dr. Robert A. Lafyatis
Rheumatology
Elite in Scleroderma
Dr. Robert A. Lafyatis
Rheumatology

University Of Pittsburgh Physicians

200 Lothrop St, 
Pittsburgh, PA 
 (0.1 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Lafyatis is a Rheumatologist in Pittsburgh, Pennsylvania. Dr. Lafyatis and is rated as a Distinguished provider by MediFind in the treatment of Scleroderma. His top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Pulmonary Fibrosis, Scleroma, and Pancreaticoduodenectomy.

Advanced in Scleroderma
Dr. Amr H. Sawalha
Rheumatology
Advanced in Scleroderma
Dr. Amr H. Sawalha
Rheumatology

University Of Pittsburgh Physicians

4401 Penn Ave, 
Pittsburgh, PA 
 (1.8 mi)
412-692-5520
Languages Spoken:
English
See accepted insurances

Amr Sawalha is a Rheumatologist in Pittsburgh, Pennsylvania. Dr. Sawalha and is rated as a Distinguished provider by MediFind in the treatment of Scleroderma. His top areas of expertise are Behcet Disease, Systemic Lupus Erythematosus (SLE), Vasculitis, and Takayasu Arteritis.

Rohit P. Aggarwal
Advanced in Scleroderma
Dr. Rohit P. Aggarwal
Rheumatology
Advanced in Scleroderma
Dr. Rohit P. Aggarwal
Rheumatology

UPMC Arthritis And Autoimmunity Center

3601 Fifth Ave, Suite 2B, 
Pittsburgh, PA 
 (0.1 mi)
412-647-6700
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Offers Telehealth

Dr. Rohit Aggarwal, MD is a Rheumatology Specialist in Pittsburgh, PA. Dr. Aggarwal has extensive experience in Rheumatologic Muscular Diseases, Osteoporosis & Screening, and Arthritis & Arthropathy. He is affiliated with medical facilities such as Upmc East and Upmc Northwest. Dr. Aggarwal is rated as an Elite provider by MediFind in the treatment of Scleroderma. His top areas of expertise are Myositis, Dermatomyositis, Polymyositis, and Antisynthetase Syndrome.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile